Evidence map›Paper›PMID 36743930›Full record

Observational studyFrontiers in endocrinology2022

Real world effectiveness of subcutaneous semaglutide in type 2 diabetes: A retrospective, cohort study (Sema-MiDiab01).

Cesare C Berra, Maria Chiara Rossi, Marco Mirani, Daniela Ceccarelli Ceccarelli, Cristina Romano, Lorenza Sassi, Elena Peretti, Giuseppe Favacchio, Ida Pastore, Laura Folini and 4 more

Open access · goldFull text readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Observational
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Cesare C BerraDepartment of Endocrine and Metabolic Diseases, I.R.C.C.S. MultiMedica - Sesto San Giovanni, Milan, Italy.
Maria Chiara RossiCORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
Marco MiraniDepartment of Internal Medicine, I.R.C.C.S Humanitas Research Hospital - Rozzano, Milan, Italy.
Daniela Ceccarelli CeccarelliDepartment of Internal Medicine, UOC Geriatrics and Diabetology, University of Pavia, Pavia, Italy.
Cristina RomanoDiabetology, Azienda Ospedaliera ASST Sette Laghi - Osp. di Circolo, Varese, Italy.
Lorenza SassiDiabetology, Azienda Ospedaliera ASST Sette Laghi - Osp. di Circolo, Varese, Italy.
Elena PerettiDiabetology, Azienda Ospedaliera ASST Sette Laghi - Osp. di Circolo, Varese, Italy.
Giuseppe FavacchioDepartment of Internal Medicine, I.R.C.C.S Humanitas Research Hospital - Rozzano, Milan, Italy.
Ida PastoreDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Laura FoliniDepartment of Endocrine and Metabolic Diseases, I.R.C.C.S. MultiMedica - Sesto San Giovanni, Milan, Italy.
Giusi GrazianoCORESEARCH - Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy.
Maria Elena LunatiDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
Sebastiano Bruno SolerteDepartment of Internal Medicine, UOC Geriatrics and Diabetology, University of Pavia, Pavia, Italy.
Paolo FiorinaDivision of Endocrinology, ASST Fatebenefratelli-Sacco, Milan, Italy.
ASST Fatebenefratelli Sacco · ITAziende Socio Sanitarie Territoriale dei Sette LaghiCenter for Outcomes Research and Clinical Epidemiology · ITIRCCS Humanitas Research Hospital · ITMultiMedica · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Aim of the present study was to evaluate the real-world impact of once-weekly (OW) subcutaneous semaglutide on different end-points indicative of metabolic control, cardiovascular risk factors, and beta-cell function in type 2 diabetes (T2D). Methods: This was a retrospective, observational study conducted in 5 diabetes clinics in Italy. Changes in HbA1c, fasting blood glucose (FBG), body weight, blood pressure, lipid profile, renal function, and beta-cell function (HOMA-B) during 12 months were evaluated. Results: Overall, 594 patients (97% GLP-1RA naïve) were identified (mean age 63.9 ± 9.5 years, 58.7% men, diabetes duration 11.4 ± 8.0 years). After 6 months of treatment with OW semaglutide, HbA1c levels were reduced by 0.90%, FBG by 26 mg/dl, and body weight by 3.43 kg. Systolic blood pressure, total and LDL-cholesterol significantly improved. Benefits were sustained at 12 months. Renal safety was documented. HOMA-B increased from 40.2% to 57.8% after 6 months (p<0.0001). Discussion: The study highlighted benefits of semaglutide on metabolic control, multiple CV risk factors, and renal safety in the real-world. Semaglutide seems to be an advisable option for preservation of β-cell function and early evidence suggests it might have a role in modifying insulin resistance (HOMA-IR), the pathogenetic basis of prediabetes and T2D.

Indexed as

Diabetes Mellitus, Type 2AgedBody WeightCohort StudiesFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedRetrospective StudiesSemaglutideGlycated HemoglobinHypoglycemic AgentsSemaglutidebeta-cell functioncardiovascular risk factorseffectivenessHbA1cinsulin resistancesemaglutidetype 2 diabetes

Identifiers

PMID36743930
PMCPMC9889982
OpenAlexW4317107805

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.